Search Results
183 Results Found for “Cardiomyopathy”
Phase III ACACIA-HCM results show significant improvements in symptoms and functional capacity with aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy.
Eplontersen did not significantly reduce cardiovascular mortality and recurrent cardiovascular events compared with placebo in the overall CARDIO-TTRansform population, according to late-breaking results presented at ESC Congress 2026 in Munich, Germany.
Late-breaking clinical research will once again be a major focus at ESC Congress 2026, taking place in Munich, Germany, from August 28–31. This year, a record 59 trials have been selected for presentation across 12 Hot Line sessions, spanning new pharmacological approaches, diagnostic strategies, devices, imaging and digital technologies.
New clinical guidelines, late-breaking trials, artificial intelligence, and an increasing focus on cardiometabolic and precision medicine are set to shape discussions at ESC Congress 2026 in Munich.
The FDA has granted orphan drug designation to AFTX-201 (Affinia Therapeutics; Waltham, MA), an investigational gene therapy, for the treatment of BAG3-associated dilated cardiomyopathy (BAG3-DCM), according to the company. The designation follows a recent FDA Fast Track designation for the same program.
Ionis Pharmaceuticals (Carlsbad, CA, USA) and AstraZeneca (Cambridge, UK) have announced that the phase 3 CARDIO-TTRansform trial (NCT04136171) of eplontersen (Wainua®; Ionis Pharmaceuticals and AstraZeneca) did not meet its primary efficacy endpoint in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Ventricular fibrillation (VF) is characterized by rapid (>300 beats a per minute), irregular electrical activation with variable electrocardiographic waveforms that prevents coordinated myocardial contraction, resulting in immediate loss of cardiac output.1 It most commonly occurs in the context of coronary ...
Cardiovascular care continues to evolve in response to increasingly complex clinical realities, where advances in intervention, electrophysiology and population health must be integrated with a more critical appraisal of long-held assumptions. Across disciplines, there is a growing recognition that improving ...
Sudden cardiac arrest (SCA) in young adults (typically defined as individuals younger than 40 years) has emerged as an important yet under-recognized public health concern. Recent estimates suggest an incidence of approximately 1–4 cases per 100,000 person-years, underscoring the clinical and epidemiological relevance ...
At EHRA 2026, late-breaking trials across ablation, devices, and drug therapy signal major shifts in arrhythmia management, highlighting both rapid innovation and key unanswered questions. We spoke to Prof Jose Luis Merino for his highlights.
Late-breaking data from the Phase 3 HOPE-3 trial of deramiocel in Duchenne muscular dystrophy, presented at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference, suggest potential benefits across cardiac and functional outcomes. The investigational first-in-class therapy is currently under review by the FDA for the treatment of DMD cardiomyopathy, with a Prescription Drug User Fee Act target action date of 22 August, 2026.
Dr Andreas Boehmer joins the Heart International Editorial Board with expertise in electrophysiology
We are pleased to announce the appointment of Dr Andreas Boehmer to the Heart International Editorial Board. Dr Boehmer is an Electrophysiology Fellow at St. Josefs-Hospital Wiesbaden in Germany, where he works within the Department of Cardiology and conducts research focused on interventional therapies for cardiac arrhythmias and the treatment of patients with tachycardiomyopathy.
The FDA has approved aficamten for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), with the aim of improving functional capacity and symptoms.
As 2025 draws to a close, we’re celebrating another remarkable year of growth, collaboration and innovation at touchCARDIO. From thought-provoking expert interviews and peer-reviewed research to dynamic conference coverage and an expanding portfolio of medical education, this year has been defined by meaningful conversations and impactful learning. We’ve had the privilege of engaging with leading clinicians, researchers and partner societies across the globe - bringing together diverse voices to support the cardiology community with timely, accessible and authoritative content. As we reflect on the past 12 months, we’re proud to highlight the moments, milestones and stories that shaped our year.
Cardiovascular medicine continues to advance at a remarkable pace, driven by innovation, interdisciplinary collaboration and an ever-deepening understanding of disease mechanisms. As patient populations age and chronic conditions become increasingly complex, the field stands at the intersection of precision therapy, ...
Heart failure (HF) is a complex and progressive clinical syndrome that significantly impacts morbidity, mortality and quality of life (QoL).1 On a global scale, HF has become an escalating public health concern, affecting more than 64 million individuals in 2017, and this ...
The Evolut Low Risk trial (Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement; ClinicalTrials.gov identifier:Â NCT02701283) provides reassuring evidence that transcatheter aortic valve replacement (TAVR) ...
The 2025 American Heart Association (AHA) Scientific Sessions (7–10 November; New Orleans, LA, USA) offered a comprehensive overview of the evolving landscape of cardiovascular medicine. This year’s research showcased pivotal trials spanning indications, including hypercholesterolemia, hypertrophic cardiomyopathy, amyloidosis, severe hypertriglyceridaemia, hypertension, ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
